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In  the  early  1950s,  Rubin  H.  Flocks  of the University  of  Iowa  began  to  treat  prostate 
cancer patients with colloidal gold (Au
198) therapy, evolving his technique over nearly 25 
years in 1515 patients. We reviewed the long-term outcomes of Flocks’ prostate cancer 
patients as compared to those patients treated by other methods at the University of 
Iowa  before  Flocks’  chairmanship.  We  reviewed  archived  patient  records,  Flocks’ 
published data, and long-term survival data from the Iowa Tumor Registry to determine 
short- and long-term outcomes of Flocks’ work with colloidal gold. We also reviewed the 
literature of Flocks’ time to compare his outcomes against those of his contemporaries. 
The use of colloidal gold, either as primary or adjunctive therapy, provided short- and 
long-term survival benefit for the majority of Flocks’ patients as compared to historical 
treatment options (p < 0.001). Flocks’ use of colloidal gold for the treatment of locally 
advanced prostate cancer offered short-  and long-term survival  benefits  compared to 
other contemporary treatments. 
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INTRODUCTION 
While interstitial implantation of radioactive materials into tumors had been explored for several decades, 
interest in its widespread clinical application grew when Rubin H. Flocks introduced the instillation of 
colloidal gold (Au
198) into the prostate and its environs during open prostate operations. In 1951, Flocks 
instilled 60 mCi of colloidal Au
198 into the prostate of an 80-year-old man with prostate cancer refractory 
to estrogen therapy[1]. This patient’s dramatic reduction in prostate volume became the index case for a 
series of 1515 men treated with colloidal gold over the next 25 years. While Flocks did not live to see his 
survival data mature, the University of Iowa Hospitals and Clinics’ Cancer Registry and the Iowa State 
Tumor Registry have allowed us to review his extensive series and report on the evolution of Flocks’ 
treatment philosophy, complications, and success in the era before early prostate cancer diagnosis with 
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THE EVOLUTION OF FLOCKS’ COLLOIDAL GOLD TREATMENT 
The lack of any effective screening tool in the early part of the 20
th century, other than digital rectal exam, 
meant that prostate cancer presented in a very different manner than is common today. Over 90% of 
patients  seen  at  the  University  of  Iowa  in  the  20  years  preceding  Flocks’  work  with  colloidal  gold 
presented  with  symptoms  of  either  locally  advanced  or  metastatic  disease,  usually  with  urinary 
obstruction[2]. In 1950, Flocks was confronted with an 80-year-old gentleman with hormonally resistant, 
locally extensive prostate cancer. Retropubic placement of radon seeds was planned, but was complicated 
mid-operation when it was discovered that the seeds were not available. Flocks immediately substituted 
60  mCi  Au
198  colloid  injected  into  the  cancer  tissue.  The  gold  colloid  was  readily  available  at  the 
institution  as  it  was  undergoing  use  for  palliation  of  intraperitoneal  metastases  in  ovarian  cancer 
patients[3]. At 1.5 years’ follow-up, the patient’s prostate had reduced to normal size.  
Earlier reports of successful prostate cancer treatment with radium implantation were complicated by 
an association with severe bowel and bladder irritation and ulceration[2]. Flocks theorized that colloidal 
gold  would  allow  more  localized  radiation  with  less  risk  to  adjacent  structures,  while  dramatically 
increasing the local dose of radiation because of the shorter half-life and beta penetration of colloidal gold 
as compared to radium. Flocks also theorized that some of the radioactive gold would be transported to 
the draining lymph nodes, where it could treat metastatic spread of the disease. 
Flocks reported his initial 20 cases of interstitial radiation with radioactive gold in 1952[1]. His 
technique  involved  a  combined  retropubic  and  intravesical  approach,  to  maximize  exposure  to  the 
prostate, seminal vesicles, and regional lymph nodes. While the majority of the radiation from colloidal 
gold  is  from  a  short-lived  and  short-traveling  beta  ray,  gamma  radiation,  with  its  greater  ability  to 
penetrate tissue and travel long distances, created the potential for significant whole-body radiation if 
given in large doses. Thus, Flocks’ original dosing approximated 3 mCi per estimated gram of tissue in 
glands weighing <25 g and 1 mCi per estimated gram of tissue for prostates weighing >150 g. While no 
long-term data were available to Flocks at the time of his 1952 publication, he reported that in 17 of 20 
cases, all palpable prostatic firmness had resolved within weeks, while significant improvement was seen 
in the remaining three cases. 
In 1955, Flocks reported on his first 100 cases of colloidal gold therapy, noting some changes in his 
operative technique[4]. These patients were carefully screened so that only those with locally advanced 
disease  would  receive  gold  therapy;  patients  with  metastatic  disease  were  excluded.  Of  his  first  50 
patients, 18 developed rectal irritation, eight of whom eventually suffered rectal ulcerations, including 
four who required a colostomy. To understand this tragic complication, Flocks spent time in the anatomy 
lab and soon discovered that the large volumes of colloidal gold he was using (up to 100 cc) were 
spreading along Denonvillier’s fascia, resulting in excess radiation to the rectum. By reducing the volume 
of gold colloid instilled, but not the millicurie content of the solution, he noted no rectal complications in 
his second group of 50 patients. He also reported efforts to ensure good distribution throughout the 
prostate using hyaluronidase with the colloidal gold. Flocks advocated repeat perineal injections weeks 
after the initial surgery if the patient’s clinical picture (based on reduction in prostate mass) did not 
improve. At 2 years’ follow-up, 46 of the first 100 treated patients were alive. 
After the first 100 cases, the pace of Flocks’ work increased and by 1957, he had performed 389 total 
cases[5]. He reported again that the most challenging issue in his technique was adequate distribution of 
the radioactive gold throughout the prostate. He used postinjection radiation scans to evaluate the distant 
spread of the colloidal gold. His next publication reported on his outcomes with 785 procedures in his 
first 517 patients treated with a range of one to seven injections of colloidal gold per patient based on 
clinical response[6]. He settled on a concentration of 1–1.5 mCi Au
198 per gram of prostate tissue (100 
mCi)  diluted  in  a  volume  of  2–4  cc.  He  also  described  further  surgical  modifications,  including 
transitioning  to  the  standard  removal  of  the  regional  pelvic  lymph  nodes  regardless  of  their  gross 
appearance  whenever  feasible.  He  based  this  decision  on  the  overall  increased  survival  he  found  in 
patients with negative lymph nodes. He also described in detail the complications resulting from his 
procedure. Four patients died while in hospital following the procedure. A review of the autopsy records Rosevear et al.: Flocks’ Colloidal Gold Treatment for Prostate Cancer  TheScientificWorldJOURNAL (2011) 11, 1560–1567 
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showed that two died of myocardial infarction and two died of pulmonary embolism. Of note, the careful 
attention to injected volume appeared to have significantly lowered the rectal ulceration complication risk 
from 16% in the first 50 patients to 0.5% in the next 467.  
In a separate publication in 1958, Flocks described his first 5-year outcomes[7]. This cohort included 
135 patients and an interesting caveat. In referring to his overall outcome of 34% survival, Flocks stated, 
“It must be remembered, however, that many of the early patients were old, decrepit, and so riddled with 
intercurrent disease that they succumbed to these conditions rather than to prostatic cancer.” This 5-year 
survival compared well against the 18% historical 5-year survival at the University of Iowa before the 
introduction of colloidal gold therapy. In reporting his outcomes in this group, he separated his patients 
by prostate size. In the <20 g group, 10 of 11 patients (91%) were alive, whereas only two of 20 (10%) 
with glands >100 g were alive. Flocks theorized that gland size was a surrogate marker for extent of 
disease and that his treatment was best for smaller-volume disease. This theory is supported by long-term 
data. Using survival data from the Iowa Tumor Registry in combination with prostate size as reported in 
Flocks’ 1959 paper on lymphatic spread of prostate cancer[8], the Kaplan-Meier curve shown in Fig. 1 
demonstrates a significant difference in survival based on prostate size. 
 
FIGURE  1.  Flocks  prostate  cancer  gold  therapy,  disease-specific  survival 
comparison by prostate size. 
Flocks later reported his experience combining colloidal gold treatment with radical prostatectomy 
for stage C lesions[9,10]. Stage C, by definition, invades the capsule and partially invades the areolar 
tissue around the prostate itself and around the base of the seminal vesicles, but has no evidence of 
metastatic  or  lymph  node  extension.  In  a  series  of  335  such  patients  with  5-year  follow-up,  Flocks 
reported a 4.4% local recurrence rate, which was dramatically lower than the 21–28% recurrence rate that 
was  being  reported  by  his  contemporaries  who  were  treating  the  disease  with  radical  prostatectomy 
alone[11]. Rosevear et al.: Flocks’ Colloidal Gold Treatment for Prostate Cancer  TheScientificWorldJOURNAL (2011) 11, 1560–1567 
 
1563 
 
By 1969, Flocks had treated 1074 patients in over 1500 separate procedures[12]. He had concluded 
by this point that if the volume of the prostate was >40 g, cure using only colloidal gold was not possible 
because  of  distribution  problems  necessitating  the  use  of  surgery  for  curative  intent.  He  also 
recommended repeat injections at 2 months, either transrectally or transperineally, to destroy any residual 
tumor. 
Flocks’ last paper on his experience with colloidal gold was published in 1973, in which he reviewed 
his long-term survival data on patients with stage C disease[13]. It was his practice in cases of locally 
advanced disease to remove the prostate if possible and then apply colloidal gold to the surrounding 
tissue, and, when the prostate could not be removed, he used electrodessication of the prostatic tissue and 
seminal vesicles to decrease the tumor mass and then instilled the radioactive colloidal gold into the 
tissue. He reported a 27.5% 15-year survival for patients with stage C disease who were lymph node 
negative at the time of surgery. This was equivalent to the results being reported by his contemporaries 
for stage A (occult disease) or stage B disease (confined to the prostate) treated with surgery alone[14]. 
LONG-TERM OUTCOMES 
Flocks,  like  all  surgeon  scientists,  was  interested  in  translating  modern  science  into  better  clinical 
outcomes for his patients. In the era before colloidal gold treatment, the 5-year survival for patients with 
prostate cancer was between 18 and 27%, based on Flocks’ own review of 854 patients treated at the 
University of Iowa and a similar series of 504 patients at the University of Michigan[15]. The use of 
colloidal gold at the University of Iowa ended in 1975 soon after Flocks died, when the colloidal version 
of Au
198 was replaced with Au
198 radioactive seeds by the manufacturer. To investigate the long-term 
outcomes of Flocks’ colloidal gold therapy for prostate cancer, the Iowa Tumor Registry examined the 
outcomes of all patients treated at the University of Iowa under Flocks’ care. A Kaplan-Meier analysis 
comparing  all  of  the  patients  Flocks  treated  with  colloidal  gold  to  the  two  series  mentioned  above 
demonstrates significant improvement in overall survival for the gold-treated patients (p < 0.001, Fig. 2). 
It is important to remember that Flocks was treating patients with locally advanced disease — T3/T4 by 
today’s staging system. Flocks divided his patients into two categories based on whether he could safely 
remove the prostate. He would perform a prostatectomy if possible, then apply the colloidal gold to the 
area immediately around the bed of the prostate; if prostatectomy was not possible, he would inject the 
colloidal gold into the prostate itself. An analysis of these two groups shows a significant survival benefit 
for those patients in whom prostatectomy was performed (p = 0.05, Fig. 3), while all three groups did 
better than either of the historical controls mentioned above (p = 0.001, figure not shown). 
A final way to compare Flocks’ success with prostatectomy and colloidal gold is to compare his long-
term survival outcomes to those of his direct contemporaries[16,17,18]. A caveat that must be stated when 
comparing these data is that Flocks was the only surgeon in this comparison group who would operate 
with  curative  intent  on  patients  felt  to  have  locally  advanced  disease.  The  other  three  distinguished 
surgeons  carefully  selected  their  patients  in  order  to  minimize  the  chance  of  local  extension.  When 
comparing these groups, Flocks’ cohort of all patients receiving gold fared the worst (p = 0.001, Fig. 4). 
Looking  at  only  the  Flocks  patients  who  underwent  total  prostatectomy,  gold  therapy  without 
concomitant orchiectomy (a surrogate marker for those Flocks patients with the least advanced disease), 
there is no significant difference in outcome between patients in all comparison groups. However, another 
group of patients still did significantly better (p = 0.05)[18].  
As previously noted, Flocks’ local recurrence rate was significantly lower than that of his peers, with 
reported rates of 28, 29, and 34%, compared to Flocks’ 17% overall recurrence rate[11,19,20], again 
suggesting a beneficial role for colloidal gold therapy.  Rosevear et al.: Flocks’ Colloidal Gold Treatment for Prostate Cancer  TheScientificWorldJOURNAL (2011) 11, 1560–1567 
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FIGURE 2. Survival analysis: Iowa prostate cancer patients pre–
gold treatment vs. Iowa gold-treated patients vs. University of 
Michigan patients[15]. 
 
FIGURE 3. Survival analysis: Iowa prostate cancer patients treated 
with gold injection only vs. those treated with prostatectomy and gold 
injection. Rosevear et al.: Flocks’ Colloidal Gold Treatment for Prostate Cancer  TheScientificWorldJOURNAL (2011) 11, 1560–1567 
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FIGURE  4.  Survival  analysis:  all  Iowa  gold-treated  patients  vs. 
contemporary prostate cancer patient reported series[16,17,18]. 
It was hypothesized in the early literature on colloidal gold therapy that venous and lymphatic spread 
of the gold may increase the risk of lymphoma[2]. While Flocks made every effort to limit the total 
millicurie injection content, theoretical and actual concerns over whole-body gamma radiation leading to 
other secondary malignancies also existed. Thus, we also reviewed the available data on all secondary 
malignancies of patients treated with colloidal gold (Table 1). No significant differences were noted in the 
number of cases of lymphoma or four other common cancers, suggesting that the two populations are 
similar in second primary risk. The only type of cancer to have statistically different incidence between 
Flocks’ cohort and the rest of the general Iowa population was stomach cancer, where six cases (0.4% of 
patients  receiving  gold  therapy)  were  reported  compared  to  13  cases  (0.2%  of  the  general  Iowa 
population; proportional incident ratio of 2.62 CI 1.21–5.70). 
CONCLUSIONS 
Flocks’  innovative  use  of  colloidal  gold  over  nearly  25  years  resulted  in  statistically  significant 
improvements  in  short-  and  long-term  survival  for  his  patients.  He  also  helped  to  advance  the 
understanding of lymph node staging for prostate cancer. He pioneered a multidisciplinary approach to 
prostate cancer treatment, drawing on the strengths of other radiation oncologists at the University of 
Iowa. His determination and continuous efforts at improving his techniques through basic science and 
anatomical research created a paradigm of translational research that is broadly used today.  
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TABLE 1 
Second 
Cancer 
Primary Site 
Flocks’ Colloidal Gold Patients,  
1951–1977 (n = 1431*) 
All Iowa Resident Prostate Cancers, 
1969–1975 (n = 6168) 
Number 
Second 
Primaries  
(n = 94) 
All Au 
Second 
Primaries 
All Au 
Prostate 
Cancers 
Number 
Second 
Primaries  
(n = 535) 
All Au 
Second 
Primaries 
All 
Prostate 
Cancers 
Stomach  6  6.4%  0.4%  13  2.4%  0.2% 
Colon/rectum  15  16.0%  1.1%  113  21.1%  1.8% 
Pancreas  5  5.3%  0.4%  20  33.7%  0.3% 
Lung/bronchus  20  21.3%  1.4%  97  18.1%  1.5% 
Urinary bladder  14  14.9%  1.0%  87  16.3%  1.4% 
Bone marrow/ 
   lymphoma
+ 
9  9.6%  0.6%  93  17.4%  1.5% 
All other sites  25  26.6%  1.7%  112  20.9%  1.8% 
*  For whom follow-up data are available. 
+  Leukemia, lymphoma, myeloma. 
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